Education
About Us
Working with TipRanks
Follow Us
Opus Genetics (IRD)
NASDAQ:IRD
IRD Stock Chart & Stats
$2.31
$0.08(5.63%)
At close: 4:00 PM EST
$2.31
$0.08(5.63%)
Day’s Range― - ―
52-Week Range$0.65 - $3.05
Previous CloseN/A
Volume154.21K
Average Volume (3M)431.43K
Market Cap
$159.31M
Enterprise Value$129.56M
Total Cash (Recent Filing)$30.82M
Total Debt (Recent Filing)$1.07M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding68,964,210
10 Day Avg. Volume559,975
30 Day Avg. Volume431,433
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.73
Price to Sales (P/S)2.89
P/FCF Ratio-1.24
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue8.85
Enterprise Value/Gross Profit158.00
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$7.75Price Target Upside235.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Proof-of-conceptConsistent visual improvements reported in LCA5 patients and initial dosing in the BEST1 trial provide early human proof-of-mechanism that could materially boost investor confidence if additional data show durable vision gains.
Manufacturing And External FundingA manufacturing agreement with a major contract manufacturer together with external funding for an externally sponsored trial lowers production and development risk and supports progression of clinical programs.
Regulatory PathwayPositive FDA interactions, including agreement on a single-arm pivotal design and recognition of expedited review pathways, could reduce regulatory uncertainty and streamline advancement of the lead LCA5 program.
Bears Say
Patient Population SizeSome target indications involve small or geographically concentrated patient populations, which could limit commercial scale and dampen revenue potential even if therapies are approved.
Program And Financing Risk ExposureThe company faces multiple risks across clinical development, regulatory review, intellectual property, and financing that could lead to delays, additional capital needs, or unfavorable outcomes for valuation.
Reliance On Partnerships For CommercializationNarrow indications and limited market size may necessitate partnerships for commercial launch, potentially reducing future revenue share and strategic control over product rollouts.
Opus Genetics News
IRD FAQ
What was Opus Genetics’s price range in the past 12 months?
Opus Genetics lowest stock price was $0.65 and its highest was $3.05 in the past 12 months.
What is Opus Genetics’s market cap?
Opus Genetics’s market cap is $159.31M.
When is Opus Genetics’s upcoming earnings report date?
Opus Genetics’s upcoming earnings report date is May 08, 2026 which is in 95 days.
How were Opus Genetics’s earnings last quarter?
Opus Genetics released its earnings results on Nov 12, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.12.
Is Opus Genetics overvalued?
According to Wall Street analysts Opus Genetics’s price is currently Undervalued.
Does Opus Genetics pay dividends?
Opus Genetics does not currently pay dividends.
What is Opus Genetics’s EPS estimate?
Opus Genetics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opus Genetics have?
Opus Genetics has 68,964,210 shares outstanding.
What happened to Opus Genetics’s price movement after its last earnings report?
Opus Genetics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -2.538%.
Which hedge fund is a major shareholder of Opus Genetics?
Currently, no hedge funds are holding shares in IRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opus Genetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (235.50% Upside)
$7.75 (235.50% Upside)
Insider Transactions
Sold Shares
Worth $8.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.24%
12-Months-Change
Fundamentals
Return on Equity
-338.75%
Trailing 12-Months
Asset Growth
-13.76%
Trailing 12-Months
Company Description
Opus Genetics
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
IRD Stock 12 Month Forecast
Average Price Target
$7.75
▲(235.50% Upside)
Technical Analysis
Ownership Overview
16.52% Insiders
2.10% Mutual Funds
0.34% Other Institutional Investors
78.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---